- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00872144
Sativex for Treatment of Chemotherapy Induced Neuropathic Pain
A Double Blind Placebo Controlled Crossover Pilot Trial of Sativex With Open Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain
Study Overview
Detailed Description
The problem of neuropathic pain:
A recent review has identified a neuropathic pain prevalence rate of 2-3% in the general population 1. Based on a Canadian population of 30 million, this means that close to one million Canadians suffer with neuropathic pain. Neuropathic pain is one of the most difficult types of persistent pain to treat effectively. No more than 50% 2 of patients with neuropathic pain obtain adequate relief using current treatments. This is related to the fact that there are numerous pathophysiological mechanisms that contribute to neuropathic pain. Neuropathic pain is now understood to involve neural responses in which both peripheral and central mechanisms contribute to the generation of spontaneous pain and evoked aspects including allodynia and hyperalgesia 3-5, Traditional approaches to neuropathic pain have involved the use of oral medications as single agents or in combination (NSAIDs, opioids, anticonvulsants, tricyclic type antidepressants) 6,7. Unfortunately this approach is often inadequate and accompanied by side effects. New treatments are needed for management of neuropathic pain
Neuropathic pain associated with chemotherapy:
Neuropathic pain associated with chemotherapy used for treatment of solid tumors (eg. paclitaxil, vincristine and cis-platin) is particularly resistant to treatment and is a growing clinical problem as chemotherapeutic regimes grow more successful in extending life. This type of neuropathic pain is particularly resistant to treatment and contributes to the overall level of suffering experienced by patients who recovering from cancer treatment with chemotherapy. There is pre-clinical evidence supporting that cannabinoid agonists may be helpful for treatment neuropathic pain caused by chemotherapy.
Cannabinoids in treatment of pain:
The potent anti-nociceptive and antihyperalgesic effects of cannabinoid agonists in animal models of acute and chronic pain, the presence of cannabinoid receptors in pain-processing areas of the brain, spinal cord and periphery and evidence supporting endogenous modulation of pain systems by cannabinoids, provide support that cannabinoids exhibit significant potential as analgesics8-13.
In addition sixteen of 19 randomized controlled trials examining cannabinoids in the treatment of pain have demonstrated a significant analgesic effect , nine of the positive trials involved neuropathic pain 14. Several of these trials examined a cannabinoid extract preparation Sativex15-20 proposed in the current trial.
What is the current standard of care for neuropathic pain caused by chemotherapy?
The current standard of care for neuropathic pain associated with chemotherapy is similar to that for management of chronic neuropathic pain. The approach consists of an interdisciplinary active participatory approach to living with incurable pain. This includes trials of pharmacotherapy (eg. anti-convulsant analgesics, tricyclic antidepressant analgesics and opioids), therapeutic exercise programs and training in coping strategies such as pacing and positive self talk. Such an approach is offered at multidisciplinary pain centres such as the Pain Management Unit (PMU) here at CDHA.
Study question:
Given the limitations of current best practice, the compelling pre-clinical work supporting that cannabinoids exhibit anti-nociceptive effects in neuropathic pain and more specifically in chemotherapy induced neuropathic pain and initial clinical trials supporting that Sativex exhibits efficacy in other types of neuropathic pain we propose a pilot trial of 30 patient to evaluate the effectiveness of Sativex in treatment of neuropathic pain caused by chemotherapy. If there are positive therapeutic effects in the pilot trial, we plan a subsequent randomized controlled trial.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Queen Elizabeth II Health Sciences Centre, Pain Management Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18 years
- Neuropathic pain beginning after chemotherapy with paclitaxil, vincristine or cis-platin that has been present for 3 months or longer.
- Presence of allodynia, hyperalgesia or hypoesthesia on sensory testing in the area of pain.
- Moderate to severe pain, as defined by an average 7-day pain score of greater than 4.0 on an 11-point numerical rating scale for pain intensity (NRS-PI).
- Medications must have been stable for at least14 days.
- Ability to follow the protocol
- Willing and able to give written informed consent.
Exclusion Criteria:
- Ischemic heart disease
- Personal history of schizophrenia or psychotic disorder
- Family history of schizophrenia or psychotic disorder in first degree family member (parent, sibling or child)
- Allergy to cannabinoids
- Presence of any other clinically significant medical disorder (other than the cancer requiring chemotherapy) on history or physical exam that would compromise the participants' safety in the trial as judged by the study physician
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sativex
|
Sativex (or placebo) will be dispensed identical 5.5 ml containers.
Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs.
If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two.
Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day.
In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation.
Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the NRS-PI from baseline to the final week of stable dose treatment)
Time Frame: Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)
|
Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)
|
Participants gaining a 30% or greater reduction in the NRS-PI
Time Frame: Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)
|
Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcome measures will include measures in the remaining domains (suggested by IMMPACT). These include SF36, Quantitative sensory examination, Global Impression of Change, PGIC and Patient Satisfaction Scale, PSS
Time Frame: After stable dosing is achieved (week 3)
|
After stable dosing is achieved (week 3)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mary E Lynch, MD, Nova Scotia Health Authority
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDHA-RS/2009-316
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
-
Ashwin ViswanathanBoston Scientific CorporationNot yet recruitingChronic Pain | Neuropathic Pain | Pain, NeuropathicUnited States
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
Clinical Trials on Sativex
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity Disorder (ADHD)United Kingdom
-
AbbottRecruiting
-
S. Andrea HospitalUniversity of Roma La SapienzaUnknown
-
Jazz PharmaceuticalsQuintiles, Inc.CompletedPain | Cancer | Palliative CareSpain, United Kingdom, United States, Canada, Poland, India, France, Czech Republic, Belgium, Romania, Chile, Finland, Germany, Italy, Mexico, South Africa
-
National Institute on Drug Abuse (NIDA)CompletedPharmacokinetics | Cannabis | Dependence | Cannabis Abuse | fMRIUnited States
-
Jazz PharmaceuticalsCompleted
-
Almirall, S.A.CompletedMultiple SclerosisItaly
-
Michael, Levy M.D.,Ph.D.Jazz PharmaceuticalsNot yet recruitingSpasticity, Muscle | NMO Spectrum DisorderUnited States
-
One World Cannabis Ltd.Completed
-
Ospedale San RaffaeleUniversity of Padova; Niguarda Hospital; Fondazione Salvatore MaugeriCompletedMotor Neuron Disease | Amyotrophic Lateral Sclerosis (ALS)Italy